Skip to content
Disclosery

TRV GP IV, LLC

Follow

13F filer, CIK 1688325, Boston, MA

TRV GP IV, LLC reported $253,684,290 across 2 holdings for the quarter ended 2026-06-30, in a 13F-HR filed 2026-08-10.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001193125-26-340720

Period
2026-06-30
Reported value
$254M
Holdings
2
Top 10 weight
100%
New
0
Sold out
0

Holdings, Q2 2026

Share positions as resolved from 13F-HR 0001193125-26-340720, largest first. % of portfolio is the value over $253,684,290, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
MAZEMAZE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 6,073,958 shares; 2025Q2: 6,073,958 shares; 2025Q3: 6,073,958 shares; 2025Q4: 4,473,958 shares; 2026Q1: 4,473,958 shares; 2026Q2: 4,473,958 shares 4,473,958$134M52.63%0Timeline
TNGXTANGO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 16,859,075 shares; 2024Q4: 16,859,075 shares; 2025Q1: 16,859,075 shares; 2025Q2: 16,859,075 shares; 2025Q3: 13,863,975 shares; 2025Q4: 7,874,574 shares; 2026Q1: 6,374,574 shares; 2026Q2: 6,374,574 shares 6,374,574$120M47.37%0Timeline

How Q2 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001193125-26-340720 base2026-08-10acceptance time not in the bulk data set